Fig. 4: Dynamic ctDNA monitoring predicts treatment response and survival outcomes. | npj Precision Oncology

Fig. 4: Dynamic ctDNA monitoring predicts treatment response and survival outcomes.

From: Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib

Fig. 4: Dynamic ctDNA monitoring predicts treatment response and survival outcomes.

Sankey plots illustrating the evolution of ctDNA status and its association with the best of response (BOR) of the three profiling paradigms: A MET-specific alterations, D Canonical (tier I/II) alterations, and G Pan-alterations. Bar charts depicting the distribution of BOR stratified by ctDNA dynamic categories (persistent negativity, clearance, or residual) for (B) MET-specific, E Canonical, and H Pan-alterations, profiling. Kaplan-Meier curves for progression-free survival (PFS) based on dynamic ctDNA status for (C) MET-specific, F Canonical, and I Pan-alterations monitoring.

Back to article page